Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

标题
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 15_suppl, Pages 4506-4506
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2020-05-25
DOI
10.1200/jco.2020.38.15_suppl.4506

向作者/读者发起求助以获取更多资源

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now